Savara plans to start enrollment in its Phase II clinical trial of AeroVanc in early April 2013. The trial is a randomized, double-blind, placebo-controlled study carried out in multiple sites around the U.S.
Members of the Clinical Advisory Board
Michael P. Boyle , M.D., F.C.C.P., Associate Professor of Medicine and Director of the Adult Cystic Fibrosis Program at Johns Hopkins Medical Institutions, Baltimore, MD.
Elliott C. Dasenbrook , M.D., M.H.S., Assistant Professor at Case Western Reserve University School of Medicine, Associate Director of the Adult Cystic Fibrosis Program at University Hospitals Case Medical Center, Cleveland, OH.
Michael W. Konstan , M.D., Professor and Chairman of the Department of Pediatrics of Case Western Reserve University School of Medicine, Director of The LeRoy W. Matthews Cystic Fibrosis Center at University Hospitals Rainbow Babies and Children's Hospital, Cleveland, OH.
Felix Ratjen , M.D., F.R.C.P.(C), Professor and Division Chief of Pediatric Respiratory Medicine at The Hospital for Sick Children, Co-leader of the Cystic Fibrosis Center at SickKids, Toronto, Canada.
Grant Waterer , M.B.B.S., F.R.A.C.P., Professor and Head of Unit at the School of Medicine and Pharmacology Royal Perth Hospital Unit at the University of Western Australia, Perth, Australia.
AeroVanc™ (vancomycin hydrochloride inhalation powder) is a proprietary inhaled dry powder form of vancomycin in a capsule-based device designed for convenient self-administration. AeroVanc is being developed for the treatment of MRSA lung infection in CF patien
|SOURCE Savara Pharmaceuticals|
Copyright©2012 PR Newswire.
All rights reserved